NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

滑膜肉瘤(SS)- 流行病學預測 2028年

Synovial sarcoma (SS) - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 915401
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 2-10個工作天內
價格
滑膜肉瘤(SS)- 流行病學預測 2028年 Synovial sarcoma (SS) - Epidemiology Forecast to 2028
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的滑膜肉瘤(SS)的2017年的罹患數2,091人估計。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的滑膜肉瘤(SS)市場調查,疾病概要,各部位、性別、年齡、病期的罹患數及診斷數的變化與預測,治療、管理的指南,未滿足需求,市場成長要素及障礙等相關資訊彙整。

目錄

第1章 重要洞察

第2章 滑膜肉瘤(SS)市場概要

  • 市場佔有率和分佈(實在數值)
  • 市場佔有率與分佈(預測值)

第3章 疾病背景和概要

  • 簡介
  • 2次類型
  • 原因和危險因素
  • 症狀
  • 病理生理學
  • 遺傳的方面
  • 惡性度分類和病期分類
  • 診斷
  • 預後
  • 滑膜肉瘤(SS)的轉移性生物標記

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的滑膜肉瘤(SS)的總罹患數
  • 主要7個國家的滑膜肉瘤(SS)的診斷數

第5章 滑膜肉瘤(SS)的流行病學:各國

  • 美國
    • 假設和根據
    • 總罹患數
    • 診斷數
    • 診斷數:各部位
    • 診斷數:性別
    • 診斷數:各年齡
    • 診斷數:各病期
  • 歐盟5國
    • 德國
      • 假設和根據
      • 總罹患數
      • 診斷數
      • 診斷數:各部位
      • 診斷數:性別
      • 診斷數:各年齡
      • 診斷數:各病期
    • 法國
      • 假設和根據
      • 總罹患數
      • 診斷數
      • 診斷數:各部位
      • 診斷數:性別
      • 診斷數:各年齡
      • 診斷數:各病期
    • 義大利
      • 假設和根據
      • 總罹患數
      • 診斷數
      • 診斷數:各部位
      • 診斷數:性別
      • 診斷數:各年齡
      • 診斷數:各病期
    • 西班牙
      • 假設和根據
      • 總罹患數
      • 診斷數
      • 診斷數:各部位
      • 診斷數:性別
      • 診斷數:各年齡
      • 診斷數:各病期
    • 英國
      • 假設和根據
      • 總罹患數
      • 診斷數
      • 診斷數:各部位
      • 診斷數:性別
      • 診斷數:各年齡
      • 診斷數:各病期
  • 日本
    • 假設和根據
    • 總罹患數
    • 診斷數
    • 診斷數:各部位
    • 診斷數:性別
    • 診斷數:各年齡
    • 診斷數:各病期

第6章 軟組織肉瘤的治療/管理的指南

  • 歐洲醫療腫瘤學會 - 成人罕見實質固態癌的歐洲網路臨床診療指南(ESMO-EURACAN-CGP)
  • 軟組織肉瘤的管理相關英國指南
  • 為了改善軟組織肉瘤的診斷和治療的NICE指南

第7章 未滿足需求

第8章 附錄

  • 調查手法

第9章 DelveInsight的服務內容

第10章 免責聲明

第11章 關於DelveInsight

目錄
Product Code: DIEI0391

DelveInsight's 'Synovial sarcoma (SS) - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Synovial sarcoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Synovial sarcoma Disease Understanding

Synovial sarcoma (SS) is a rare malignancy of mesenchymal origin, accounting for approximately 8-10% of all soft tissue sarcomas (STS). SS can occur in almost any anatomic site, and, although it arises more often from the soft tissue, primary SS of the bone has also described. Despite its name, synovial sarcoma is not related to the synovial tissues that are a part of the joints. The disease starts most commonly in the legs or arms, but it can appear in any part of the body.

Synovial Sarcoma Epidemiology

The Synovial sarcoma (SS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Synovial sarcoma are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Synovial Sarcoma Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident cases , diagnosed incident cases, Site-specific incidence, gender-specific incidence, age-specific incidence, stage-specific incidence) scenario of Synovial Sarcoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of Incident cases of Synovia Sarcoma in 7 MM was found to be 2091 in the year 2017.

Report Scope

  • The report covers the descriptive overview of Synovial Sarcoma (SS) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment pattern
  • Comprehensive insight has been provided into the epidemiology of the SS in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, the UK) & Japan
  • The Report helps to recognize the growth opportunities in the 7 MM with respect to the patient population

Epidemiology Segments

  • Total incident cases
  • Diagnosed incident cases
  • Site-specific incidence
  • Gender-specific incidence, Age-specific incidence
  • Stage-specific incidence

Key strengths

  • 10 Years Forecast of Synovial Sarcoma
  • 7MM Coverage
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Synovial Sarcoma Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Synovial Sarcoma Market in 2017
  • 2.2. Market Share (%) Distribution of Synovial Sarcoma Market in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Subtypes
  • 3.3. Causes and risk factors
  • 3.4. Symptoms
  • 3.5. Pathophysiology
  • 3.6. Genetic aspect of synovial sarcoma
  • 3.7. Grading and staging of soft tissue sarcoma
  • 3.8. Diagnosis
  • 3.9. Prognosis
  • 3.10. Metastatic biomarkers in Synovial Sarcoma

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Incident Patient Population of Synovial Sarcoma
  • 4.3. 7MM Diagnosed Incident Patient Population of Synovial Sarcoma

5. Country Wise-Epidemiology of Synovial Sarcoma

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Incident Cases of SS
    • 5.1.3. Diagnosed Incidence of SS
    • 5.1.4. Site Specific Diagnose incident cases of SS
    • 5.1.5. Gender Specific diagnosed incident cases of SS
    • 5.1.6. Age Specific diagnosed incident cases of SS
    • 5.1.7. Stage Specific diagnosed Incident of cases of SS
  • 5.2. EU5 Countries
    • 5.2.1. Assumptions and Rationale
  • 5.3. Germany
    • 5.3.1. Total Incident Cases of SS
    • 5.3.2. Diagnosed Incidence of SS
    • 5.3.3. Site Specific diagnosed incident cases of SS
    • 5.3.4. Gender Specific diagnosed incident cases of SS
    • 5.3.5. Age Specific diagnosed incident cases of SS
    • 5.3.6. Stage Specific diagnosed Incident of cases of SS
  • 5.4. France
    • 5.4.1. Total Incident Cases of SS
    • 5.4.2. Diagnosed Incidence of SS
    • 5.4.3. Site Specific diagnosed incident cases of SS
    • 5.4.4. Gender Specific diagnosed incident cases of SS
    • 5.4.5. Age Specific diagnosed incident cases of SS
    • 5.4.6. Stage Specific diagnosed Incident of cases of SS
  • 5.5. Italy
    • 5.5.1. Total Incident Cases of SS
    • 5.5.2. Diagnosed Incidence of SS
    • 5.5.3. Site Specific diagnosed incident cases of SS
    • 5.5.4. Gender Specific diagnosed incident cases of SS
    • 5.5.5. Age Specific diagnosed incident cases of SS
    • 5.5.6. Stage Specific diagnosed Incident of cases of SS
  • 5.6. Spain
    • 5.6.1. Total Incident Cases of SS
    • 5.6.2. Diagnosed Incidence of SS
    • 5.6.3. Site Specific diagnosed incident cases of SS
    • 5.6.4. Gender Specific diagnosed incident cases of SS
    • 5.6.5. Age Specific diagnosed incident cases of SS
    • 5.6.6. Stage Specific diagnosed Incident of cases of SS
  • 5.7. United Kingdom
    • 5.7.1. Total Incident Cases of SS
    • 5.7.2. Diagnosed Incidence of SS
    • 5.7.3. Site Specific diagnosed incident cases of SS
    • 5.7.4. Gender Specific incident cases of SS
    • 5.7.5. Age Specific diagnosed incident cases of SS
    • 5.7.6. Stage Specific diagnosed Incident of cases of SS
  • 5.8. Japan
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Total Incident Cases of SS
    • 5.8.3. Diagnosed Incidence of SS
    • 5.8.4. Site Specific diagnosed incident cases of SS
    • 5.8.5. Gender Specific diagnosed incident cases of SS
    • 5.8.6. Age Specific diagnosed incident cases of SS
    • 5.8.7. Stage Specific diagnosed Incident of cases of SS

6. Guidelines for Treatment/ Management of Soft-Tissue Sarcoma

  • 6.1. European Society for Medical Oncology- European Reference Network for rare adult solid cancers Clinical Practice Guidelines (ESMO-EURACAN-CGP): for Soft-Tissue Sarcoma
  • 6.2. UK Guidelines for Management of Soft-tissue Sarcomas
  • 6.3. NICE Guidelines for Improving Diagnosis and Treatment of Soft-Tissue Sarcoma

7. Unmet needs

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

  • Table 1: Total Incident Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Table 2: Total Diagnosed Incident Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Table 3: Total Incident Cases of Synovial Sarcoma in the US (2017-2028)
  • Table 4: Diagnosed Incidence of SS in the United States (2017-2028)
  • Table 5: Site Specific Diagnose incident cases of SS in the United States (2017-2028)
  • Table 6: Gender Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Table 7: Age Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Table 8: Stage Specific diagnosed Incident of cases of SS in the United States (2017-2028)
  • Table 9: Total Incident Cases of Synovial Sarcoma in Germany (2017-2028)
  • Table 10: Diagnosed Incidence of SS in Germany (2017-2028)
  • Table 11: Site Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 12: Gender Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 13: Age Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 14: Stage Specific diagnosed Incident of cases of SS in Germany (2017-2028)
  • Table 15: Total Incident Cases of Synovial Sarcoma in France (2017-2028)
  • Table 16: Diagnosed Incidence of SS in France (2017-2028)
  • Table 17: Site Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 18: Gender Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 19: Age Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 20: Stage Specific diagnosed Incident of cases of SS in France (2017-2028)
  • Table 21: Total Incident Cases of Synovial Sarcoma in Italy (2017-2028)
  • Table 22: Diagnosed Incidence of SS in Italy (2017-2028)
  • Table 23: Site Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 24: Gender Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 25: Age Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 26: Stage Specific diagnosed Incident of cases of SS in Italy (2017-2028)
  • Table 27: Total Incident Cases of Synovial Sarcoma in Spain (2017-2028)
  • Table 28: Diagnosed Incidence of SS in Spain (2017-2028)
  • Table 29: Site Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 30: Gender Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 31: Age Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 32: Stage Specific diagnosed Incident of cases of SS in Spain (2017-2028)
  • Table 33: Total Incident Cases of Synovial Sarcoma in the UK (2017-2028)
  • Table 34: Diagnosed Incidence of SS in the UK (2017-2028)
  • Table 35: Site Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 36: Gender Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 37: Age Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 38: Stage Specific diagnosed Incident of cases of SS in the UK (2017-2028)
  • Table 39: Total Incident Cases of Synovial Sarcoma in Japan (2017-2028)
  • Table 40: Diagnosed Incidence of SS in Japan (2017-2028)
  • Table 41: Site Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Table 42: Gender Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Table 43: Age Specific incident cases of SS in Japan (2017-2028)
  • Table 44: Stage Specific diagnosed Incident of cases of SS in Japan (2017-2028)

List of Figures

  • Figure 1: Subtypes of Synovial Sarcoma
  • Figure 2: Risk factors associated with Synovial Sarcoma
  • Figure 3: SYT-SSX fusion
  • Figure 4: Protein interaction domains involved in synovial sarcoma
  • Figure 5: Relationship between SS18, SS18-SSX and the BAF complex
  • Figure 6: Genomic changes associated with Synovial Sarcoma
  • Figure 7: Biomarkers in Synovial Sarcoma
  • Figure 8: Total Incident Patient Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Figure 9: Total Diagnosed Patient Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Figure 10: Total Incident Cases of Synovial Sarcoma in the US (2017-2028)
  • Figure 11: Diagnosed Incidence of SS in the United States (2017-2028)
  • Figure 12: Site Specific Diagnose incident cases of SS in the United States (2017-2028)
  • Figure 13: Gender Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Figure 14: Age Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Figure 15: Stage Specific diagnosed Incident of cases of SS in the United States (2017-2028)
  • Figure 16: Total Incident Cases of Synovial Sarcoma in Germany (2017-2028)
  • Figure 17: Diagnosed Incidence of SS in Germany (2017-2028)
  • Figure 18: Site Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 19: Gender Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 20: Age Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 21: Stage Specific diagnosed Incident of cases of SS in Germany (2017-2028)
  • Figure 22: Total Incident Cases of Synovial Sarcoma in France (2017-2028)
  • Figure 23: Diagnosed Incidence of SS in France (2017-2028)
  • Figure 24: Site Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 25: Gender Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 26: Age Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 27: Stage Specific diagnosed Incident of cases of SS in France (2017-2028)
  • Figure 28: Total Incident Cases of Synovial Sarcoma in Italy (2017-2028)
  • Figure 29: Diagnosed Incidence of SS in Italy (2017-2028)
  • Figure 30: Site Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 31: Gender Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 32: Age Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 33: Stage Specific diagnosed Incident of cases of SS in Italy (2017-2028)
  • Figure 34: Total Incident Cases of Synovial Sarcoma in Spain (2017-2028)
  • Figure 35: Diagnosed Incidence of SS in Spain (2017-2028)
  • Figure 36: Site Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 37: Gender Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 38: Age Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 39: Stage Specific diagnosed Incident of cases of SS in Spain (2017-2028)
  • Figure 40: Total Incident Cases of Synovial Sarcoma in the UK (2017-2028)
  • Figure 41: Diagnosed Incidence of SS in the UK (2017-2028)
  • Figure 42: Site Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 43: Gender Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 44: Age Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 45: Stage Specific diagnosed Incident of cases of SS in the UK (2017-2028)
  • Figure 46: Total Incident Cases of Synovial Sarcoma in Japan (2017-2028)
  • Figure 47: Diagnosed Incidence of SS in Japan (2017-2028)
  • Figure 48: Site Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Figure 49: Gender Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Figure 50: Age Specific incident cases of SS in Japan (2017-2028)
  • Figure 51: Stage Specific diagnosed Incident of cases of SS in Japan (2017-2028)
  • Figure 52: The Multi-disciplinary judgment approach
  • Figure 53: Management of Localized clinically resectable STSs
  • Figure 54: Synovial Sarcoma unmet needs